1. James E. Barrett. Handbook of Experimental Pharmacology. The pharmacology of bile acids and their receptors. 1st edition. 2019. Page – 13.
2. Frederik Nevens, Pietro Andreone, Giuseppe Mazzella, Simone I Strasser, Christopher Bowlus, Pietro Invernizzi, Joost P H Drenth, Paul J Pockros, Jaroslaw Regula, Ulrich Beuers 1, Michael Trauner, David E Jones, Annarosa Floreani, Simon Hohenester, Velimir Luketic, Mitchell Shiffman, Karel J van Erpecum, Victor Vargas, Catherine Vincent, Gideon M Hirschfield, Hemant Shah, Bettina Hansen, Keith D Lindor, Hanns-Ulrich Marschall, Kris V Kowdley, Roya Hooshmand-Rad, Tonya Marmon, Shawn Sheeron, Richard Pencek, Leigh MacConell, Mark Pruzanski, David Shapiro, POISE Study Group. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. NIH. National Library of Medicine, National center for biotechnology information. Pubmed.gov. August 2016. [Accessed on 8th August 2022] https://pubmed.ncbi.nlm.nih.gov/27532829/
3. Intercept Pharmaceuticals. Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE). NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on March 2008] [Accessed on 8th August 2022] https://clinicaltrials.gov/ct2/show/NCT03439254
4. Almac Pharma Services. Electronic Medicines Compendium (EMC). [Revised in March 2018] [Accessed on 8th August 2022] https://www.medicines.org.uk/emc/files/pil.2561.pdf
5. Intercept Pharmaceuticals, Inc. U.S. Food & Drug Administration. [Revised in January 2018] [Accessed on 8th August 2022] https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207999s003lbl.pdf